NANJING, China, May 28, 2026
Nanjing-based Leads Biolabs announced that updated Phase II clinical data for its proprietary PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) have been selected for an oral presentation at the World Conference on Lung Cancer (WCLC) 2026, one of the world’s leading scientific meetings focused on lung cancer research and treatment. The presentation will take place during the conference scheduled for September 12–15, 2026, highlighting the company’s latest advances in first-line treatment for non-small cell lung cancer (NSCLC).
Expanded Phase II Data Show Durable Tumor Responses
The upcoming oral presentation will feature updated efficacy and safety findings from an expanded patient cohort evaluating Opamtistomig combined with chemotherapy for first-line NSCLC treatment. Earlier clinical data from a smaller 18-patient dataset had already demonstrated a compelling objective response rate (ORR) along with encouraging tumor shrinkage trends.
According to the company, the latest analysis includes a larger patient population and longer follow-up duration, showing that tumor responses continued to deepen over time across multiple NSCLC subgroups. These include first-line non-squamous NSCLC, first-line squamous NSCLC, and immunotherapy-pretreated non-squamous NSCLC patients.
The company stated that updated findings continue to demonstrate high response rates, durable disease control, and sustained tumor shrinkage while maintaining a safety profile consistent with earlier observations. The results reinforce the therapeutic potential of Opamtistomig as a differentiated next-generation immuno-oncology treatment candidate.
Advertisement
Bispecific Antibody Designed for Safer 4-1BB Activation
Opamtistomig is built on Leads Biolabs’ proprietary X-body platform, which enables conditional activation of the 4-1BB pathway only in the presence of PD-L1-expressing tumor cells. This targeted approach is designed to improve anti-tumor immune activation while minimizing the systemic toxicities that have historically limited earlier 4-1BB therapies.
The company highlighted that more than 600 patients have been enrolled across multiple studies evaluating Opamtistomig both as monotherapy and in combination regimens. No dose-limiting toxicities have been observed to date, and the maximum tolerated dose has not yet been reached at doses up to 25.0 mg/kg.
Leads Biolabs believes the combination of broad anti-tumor activity, durable efficacy trends, and a manageable safety profile positions Opamtistomig as a potential “IO 2.0” backbone therapy across multiple solid tumors.
Broad Clinical Development Across Multiple Tumor Types
Beyond NSCLC, the company is advancing Opamtistomig across 13 solid tumor indications, including small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (EP-NEC), and biliary tract cancer (BTC). The company stated that the therapy has shown either first-in-class or best-in-class potential in several tumor settings.
Leads Biolabs also reported that longer follow-up data from ongoing studies continue to show trends toward improved long-term survival outcomes. These findings are expected to strengthen the therapy’s competitive position in the rapidly evolving immuno-oncology landscape.
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said the oral presentation selection by WCLC reflects strong international recognition of Opamtistomig’s innovative mechanism and clinical potential in first-line NSCLC. He added that the company remains focused on advancing the therapy toward becoming a globally important immunotherapy platform.
The WCLC 2026 presentation is expected to provide a major update for investors, clinicians, and oncology researchers tracking next-generation bispecific antibody development in lung cancer treatment.
Source: Leads Biolabs press release
